At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash

Corinne Muirhead, Deborah Verzasconi, Shyam Joshi

Research output: Contribution to journalLetterpeer-review

5 Scopus citations

Abstract

As elexacaftor/tezacaftor/ivacaftor has proven to have robust clinical efficacy for eligible persons with cystic fibrosis, desensitization should be offered to those with maculopapular eruption hypersensitivity reactions to achieve tolerance. As presented in this case, if provided with tools for crushing and mixing the medication, a successful escalation protocol can be completed at home without coordinating the help of a compound pharmacy.

Original languageEnglish (US)
Pages (from-to)1779-1781
Number of pages3
JournalPediatric pulmonology
Volume57
Issue number7
DOIs
StatePublished - Jul 2022

Keywords

  • Trikafta
  • cystic fibrosis
  • desensitization
  • drug rash
  • maculopapular eruption

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash'. Together they form a unique fingerprint.

Cite this